Genmab — Februar 2018

Teller

Solsen - Hvilken dosis (stand alone eller combo) er denne aarlige behandlingspris baseret paa?

E_L

how much does
CyborD cost?

Bulder

The only drug of the three still patented is bor (Velcade), and it will run out of patent in Europe next year.

Bulder

One unit is DKK 10.051 https://min.medicin.dk/Medicin/Praeparater/3370

Teller

Hvis der anvendes lavere dosis i combo behandling med dara, bliver det vel ikke noedvendigvis mere omkosteligt at behandle. (ud over de +20% om aaret som mere eller mindre er normalen)

Teller

(www.chicagotribune.com)

Bulder

Later this year we

Bulder

... we'll have data from the Cassiopeia study with thalidomide in stead of lenalidomide. So no wonder Celgene raises prices before it's too late.

Solsen

Yes thats what it is. Short CELG

Bulder

The Irish MD, with whom I saw a video the other day, spoke about "financial toxicity", meaning that they wouldn't dream of paying for a Rev-containing combo with dara. And therefore they run their own local Irish study of dara+CyBorD.

E_L

Solsen

I also think it will kill CELG in the long run. And perhaps you are right that they have seen the end and use the time up to that to get the best outcome.

Solsen

https://clinicaltrials.gov/ct2/show/NCT02951819?recrs=a&cond=Daratumumab&draw=4&rank=37 Data could be due in this CyBorD+Dara

Thomas

Der nævnes ofte at Gen guider konservativt, det er da uden hold i virkeligheden. Så måske vi alle skulle tage deres guidance ganske seriøst...

Thomas

Tillader mig at poste dette link fra forleden igen http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=765390&isEPVantage=yes

Thomas

Også her tales der om at Revlimid efterhånden opfattes som en konkurrent. Det er efterhånden et lidt andet billede end der har været tegnet for 1-2 år siden hvor mere så Revlimid som en ‘ven’. Tager jeg fejl?

Teller

If guidance is set under 2B it would mean a growth of 60% approximately. That would be half of the growth from 16 -17 (117%). Is that even realistic with the market uptake, label expansion, and the expected approvals later this year? Or am I missing something major?

Solsen

I belive its realistic and approved

Bulder

Thomas: Det er påvist at både dara og Rev har fordele af at indgå i kombi med hinanden. Der er synergistisk effekt. Så i den forstand er de oplagte 'venner'. Imidlertid er der sket det på det sidste at Celgene har hævet prisen på Rev ganske voldsomt, så kombinationen bliver meget dyr, hvilket kan tvinge hospitalerne (forsikringerne) til at undlade den ene komponent. Her er vi så heldige at dara er (bliver) testet i langt billigere kombinationer, så dara står stærkt på markedet uanset Revs pris.

Solsen

https://www.myeloma.org/blog/dr-duries/daratumumab-news-again-showing-benefit-frontline-and-relapse Lidt tanker fra Durie på det vi har talt om i aften.